drugset / Trial / NCT00386555

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

NCT00386555

Phase 2 Withdrawn Arog Pharmaceuticals, Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.

Timeline

Start
2007-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule
Subject Crenolanib Small molecule
Background Docetaxel Small molecule